{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:57:28Z","timestamp":1771495048812,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Key Research and Development Project of Shandong Province","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}]},{"name":"Key Research and Development Project of Shandong Province","award":["2019GSF108038"],"award-info":[{"award-number":["2019GSF108038"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.bioorg.2020.103671","type":"journal-article","created":{"date-parts":[[2020,2,16]],"date-time":"2020-02-16T04:07:48Z","timestamp":1581826068000},"page":"103671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity"],"prefix":"10.1016","volume":"97","author":[{"given":"Yang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fansheng","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bioorg.2020.103671_b0005","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"Martini","year":"2014","journal-title":"Ann. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2020.103671_b0010","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/bcp.13021","article-title":"AKT in cancer: new molecular insights and advances in drug development","volume":"82","author":"Mundi","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2020.103671_b0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13045-016-0371-1","article-title":"Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer","volume":"10","author":"Massihnia","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.bioorg.2020.103671_b0020","first-page":"6105","article-title":"Overexpression and overactivation of Akt in thyroid carcinoma","volume":"61","author":"Ringel","year":"2001","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bioorg.2020.103671_b0025","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1568009611313030002","article-title":"Diverse mechanisms of AKT pathway activation in human malignancy","volume":"13","author":"Cheung","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bioorg.2020.103671_b0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1155\/2013\/756134","article-title":"AKT kinase pathway: a leading target in cancer research %J","volume":"2013","author":"Kumar","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/j.bioorg.2020.103671_b0035","article-title":"AKT as a therapeutic target for cancer","author":"Song","year":"2019","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bioorg.2020.103671_b0040","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2020.103671_b0045","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.bioorg.2020.103671_b0050","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1080\/10428194.2016.1248965","article-title":"The molecular pathogenesis of mantle cell lymphoma","volume":"58","author":"Vogt","year":"2017","journal-title":"Leukemia Lymphoma"},{"issue":"5","key":"10.1016\/j.bioorg.2020.103671_b0055","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bioorg.2020.103671_b0060","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13603","article-title":"Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma","volume":"171","author":"Oki","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.bioorg.2020.103671_b0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/15384101.2017.1403689","article-title":"Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies","volume":"17","author":"Prabhu","year":"2018","journal-title":"Cell Cycle (Georgetown, Tex.)"},{"key":"10.1016\/j.bioorg.2020.103671_b0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2017.06.067","article-title":"Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity","volume":"138","author":"Liu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2020.103671_b0075","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ardp.201500427","article-title":"Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors","volume":"349","author":"Liu","year":"2016","journal-title":"Arch. Pharm."},{"issue":"8","key":"10.1016\/j.bioorg.2020.103671_b0080","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1039\/C8MD00197A","article-title":"Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant","volume":"9","author":"Zhang","year":"2018","journal-title":"MedChemComm"},{"issue":"3","key":"10.1016\/j.bioorg.2020.103671_b0085","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bioorg.2020.103671_b0090","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bioorg.2020.103671_b0095","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2008-02-137737","article-title":"AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines","volume":"113","author":"Levy","year":"2009","journal-title":"Blood"},{"issue":"38","key":"10.1016\/j.bioorg.2020.103671_b0100","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1038\/sj.onc.1210343","article-title":"Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition","volume":"26","author":"Han","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.bioorg.2020.103671_b0105","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1158\/0008-5472.CAN-07-5783","article-title":"Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity","volume":"68","author":"Rhodes","year":"2008","journal-title":"Cancer Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819321625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206819321625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:00:28Z","timestamp":1758614428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206819321625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":21,"alternative-id":["S0045206819321625"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103671","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103671"}}